德国骨科-老年科协同管理在脆性骨折后的费用、骨质疏松治疗及再骨折评估
这项基于德国保险数据的回顾性队列研究纳入2014-2018年发生脆性骨折的80岁及以上患者,比较认证骨科-老年科协同管理(ATZ)组、未认证OGCM组与常规照护组在6个月和12个月内的医疗费用、处方药物及再骨折。结果显示ATZ和OGCM组总平均住院费用显著更高,但大多数骨折部位的再骨折费用或抗骨质疏松药物费用无显著差异,尽管髋部、骨盆和肱骨骨折的抗骨质疏松药物处方更常见。
要点
- ATZ与OGCM组所有骨折部位的总平均住院费用均显著高于常规照护组。
- 髋部、骨盆和肱骨骨折中,ATZ与OGCM组的抗骨质疏松药物处方显著更常见。
- 大多数骨折部位的再骨折费用或抗骨质疏松药物费用未见显著差异。
核心结论
- ATZ和OGCM医院在12个月内的观察到的医疗费用更高。
- 两组在大多数骨折部位的抗骨质疏松药物处方更常见,但相应的药物费用未增加。
研究设计与样本
- 回顾性队列研究,基于德国健康与长期护理保险数据。
- 对象为80岁及以上、2014-2018年发生脆性骨折的患者,分为ATZ组、OGCM组和常规照护对照组。
- 采用加权gamma模型和两部分模型,并应用熵平衡以处理缺乏随机化的问题,所有分析按骨折部位分层。
主要发现
- 12个月随访共观察206,273例患者,其中ATZ组14,100例、OGCM组133,353例、其他医院58,820例。
- ATZ和OGCM组所有骨折部位的总平均住院费用显著高于对照组。
- 大多数骨折部位的再骨折费用或抗骨质疏松药物费用未见显著差异。
- 髋部、骨盆和肱骨骨折中,ATZ和OGCM组的抗骨质疏松药物处方显著更常见。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Orthogeriatric co-management (OGCM) may provide benefits for geriatric fragility fracture patients in terms of more frequent osteoporosis treatment and fewer re-fractures. Yet, we did not find higher costs in OGCM hospitals for re-fractures or antiosteoporotic medication for most fracture sites within 12 months, although antiosteoporotic medication was more often prescribed. PURPOSE: Evidence suggests benefits of orthogeriatric co-management (OGCM) for hip fracture patients. Yet, evidence for other fractures is rare. The aim of our study was to conduct an evaluation of economic and health outcomes after the German OGCM for geriatric fragility fracture patients. METHODS: This retrospective cohort study was based on German health and long-term care insurance data. Individuals were 80 years and older, sustained a fragility fracture in 2014-2018, and were treated in hospitals certified for OGCM (ATZ group), providing OGCM without certification (OGCM group) or usual care (control group). Healthcare costs from payer perspective, prescribed medications, and re-fractures were investigated within 6 and 12 months. We used weighted gamma and two-part models and applied entropy balancing to account for the lack of randomization. All analyses were stratified per fracture site. RESULTS: We observed 206,273 patients within 12-month follow-up, of whom 14,100 were treated in ATZ, 133,353 in OGCM, and 58,820 in other hospitals. Total average inpatient costs per patient were significantly higher in the OGCM and particularly ATZ group for all fracture sites, compared to control group. We did not find significant differences in costs for re-fractures or antiosteoporotic medication for most fracture sites, although antiosteoporotic medication was significantly more often observed in the OGCM and particularly ATZ group for hip, pelvic, and humerus fractures. CONCLUSION: The observed healthcare costs were higher in ATZ and OGCM hospitals within 12 months. Antiosteoporotic medication was prescribed more often in both groups for most fracture sites, although the corresponding medication costs did not increase.
引用
- Konnopka C, Büchele G, Jaensch A, et al. Evaluation of costs, osteoporosis treatment, and re-fractures in German collaborative orthogeriatric care after fragility fractures. Osteoporos Int. 2023. PMID: 37940697. doi:10.1007/s00198-023-06965-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。